A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

NCT02411448 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

545

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Non-Small Cell Lung Cancer

Interventions

DRUG: Ramucirumab
DRUG: Placebo
DRUG: Erlotinib
DRUG: Gefitinib
DRUG: Osimertinib

Sponsor

Eli Lilly and Company